Sangamo said it plans to explore all options to commercialise the asset, including seeking a potential new collaboration partner.

PTS-500 is under clinical development by Gongwin Biopharm and currently in Phase II for Non-Small Cell Lung Cancer.

Global rare disease company Immedica Pharma has agreed to acquire Marinus Pharmaceuticals for an enterprise value of approximately $151m.

ZX-4081 is under clinical development by Hangzhou Zenshine Pharmaceuticals and currently in Phase I for Melanoma.

A-319 is under clinical development by ITabMed and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData, Phase I drugs for Systemic Lupus Erythematosus have a 73% phase ...

EEDVD-682 is under clinical development by EnGeneIC and currently in Phase II for Melanoma. According to GlobalData, Phase II drugs for Melanoma have a 27% phase transition success rate (PTSR) ...

Muzastotug is under clinical development by Adagene Suzhou and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II drugs for Metastatic Melanoma have a 36% phase ...

SCO-267 is under development for the treatment of non-alcoholic steatohepatitis (NASH), diabetes, nonalcoholic fatty liver disease and obesity. It acts by targeting GPR40. It is administered through ...

SX-682 is under clinical development by Syntrix Pharmaceuticals and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success ...

DF-003 is under clinical development by Drug Farm and currently in Phase I for Unspecified Ophthalmological Disorders.

NVP-1805R2 is under clinical development by NVP Healthcare and currently in Phase I for Unspecified Cardiovascular Disorders.

Vilastobart is under clinical development by Xilio Therapeutics and currently in Phase II for Uterine Cancer. According to GlobalData, Phase II drugs for Uterine Cancer have a 30% phase transition ...